Gossamer Bio - GOSS Stock Forecast, Price & News

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Wall Street Analysts Forecast Growth

GOSS has been the subject of several recent research reports. Piper Sandler reduced their target price on shares of Gossamer Bio from $26.00 to $15.00 in a report on Monday, April 25th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Gossamer Bio in a report on Thursday, July 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Gossamer Bio in a report on Monday, May 9th. Barclays cut their price target on shares of Gossamer Bio from $18.00 to $12.00 and set an "overweight" rating for the company in a research note on Tuesday, April 26th. Finally, Raymond James increased their price target on shares of Gossamer Bio from $10.00 to $14.00 and gave the company an "outperform" rating in a research note on Thursday, July 14th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $18.00.

Gossamer Bio Stock Performance

Shares of GOSS traded up $0.62 during trading hours on Friday, hitting $13.87. The company had a trading volume of 967,512 shares, compared to its average volume of 1,019,957. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -4.36 and a beta of 1.05. The business has a fifty day moving average of $9.34 and a 200-day moving average of $8.85. Gossamer Bio has a 12 month low of $5.64 and a 12 month high of $14.30. The company has a quick ratio of 8.12, a current ratio of 5.24 and a debt-to-equity ratio of 7.44.

Gossamer Bio (NASDAQ:GOSS - Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.04). Equities analysts anticipate that Gossamer Bio will post -2.64 EPS for the current fiscal year.

Insider Activity

In related news, CEO Faheem Hasnain acquired 138,696 shares of the company's stock in a transaction dated Friday, July 15th. The shares were bought at an average cost of $7.21 per share, with a total value of $999,998.16. Following the completion of the transaction, the chief executive officer now directly owns 3,617,325 shares of the company's stock, valued at $26,080,913.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In other Gossamer Bio news, insider Laura Carter purchased 6,934 shares of the stock in a transaction that occurred on Friday, July 15th. The shares were acquired at an average cost of $7.21 per share, with a total value of $49,994.14. Following the completion of the transaction, the insider now owns 87,168 shares in the company, valued at $628,481.28. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Faheem Hasnain purchased 138,696 shares of the stock in a transaction that occurred on Friday, July 15th. The shares were acquired at an average cost of $7.21 per share, for a total transaction of $999,998.16. Following the completion of the transaction, the chief executive officer now owns 3,617,325 shares of the company's stock, valued at approximately $26,080,913.25. The disclosure for this purchase can be found here. Insiders have purchased 159,499 shares of company stock valued at $1,149,988 over the last ninety days. 8.30% of the stock is currently owned by company insiders.